Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 634 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Teacher Reads To Students One Day After Having Brain Surgery October 26, 2021 Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... May 31, 2024 After a Breast Cancer Diagnosis, Men May Be More Likely to... October 2, 2019 Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 Load more HOT NEWS NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia Coronavirus reports – Part 9: “I am very relieved but I... Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome If You Let It, Nursing Will Change Your Life
